XENE, CA98420N1050

Xenon grants 28,350 awards: target for Xenon Pharmaceuticals stock is USD 73.00

Published on 10/18/2026 at 12:33 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Guggenheim set a USD 73.00 target on October 6, 2026. Xenon Pharmaceuticals stock had a USD 3.2 billion market value on October 16, 2026.

Regulatory path and valuation

  • On October 2, 2026, Xenon granted 17,850 options and 10,500 restricted share units to eight employees.
  • Second-quarter 2026 adjusted earnings per share were USD -1.11 versus a USD -1.16 consensus estimate.
  • Xenon Pharmaceuticals had a USD 3.2 billion market value on October 16, 2026.
  • Topline data from X-NOVA2 are expected in the first quarter of 2027.
XENE, CA98420N1050, Illustration mit AI erstellt.

Xenon Pharmaceuticals granted 17,850 stock options and 10,500 restricted share units to eight new employees on October 2, 2026, while Guggenheim opened coverage with a USD 73.00 target on October 6, 2026. The awards point to ongoing hiring, while the target keeps valuation tied to azetukalner's clinical and regulatory path, as BioSpace and MarketBeat reported.

Three events shape the story

The chronology starts with Xenon's quarterly update on August 6, 2026. The company reported adjusted earnings per share of USD -1.11, compared with a consensus estimate of USD -1.16, a USD 0.05 improvement against expectations, according to MarketBeat.

On September 17, 2026, Xenon submitted an application to the U.S. Food and Drug Administration for azetukalner in focal seizures. The release also said X-NOVA2 had reached approximately 360 enrolled patients and that topline data were expected in the first quarter of 2027, as BioSpace reported.

What does the hiring mean?

The October 2 grant package covers 17,850 options and 10,500 restricted share units, with the options carrying a USD 38.93 exercise price and a four-year vesting schedule. That structure links the awards to employee retention rather than to a new clinical milestone. It also places the grant price below Guggenheim's USD 73.00 target, although the two figures refer to different instruments and dates.

Dates investors can track

The next dated development is the first-quarter 2027 topline readout for X-NOVA2. Xenon's September 17 update said the company had paused new enrollment in certain psychiatry studies while continuing epilepsy studies, making the regulatory filing and the psychiatry data the two central milestones in the pipeline.

Valuation reflects clinical risk

Xenon was last at USD 33.49 on Nasdaq on October 16, 2026 at 4:00 p.m. ET. Its market capitalization was USD 3.2 billion on that date, while the 52-week range was USD 33.38 to USD 72.66. The spread between the market value and the USD 73.00 target shows how heavily the valuation depends on execution and regulatory progress. The further course of trading is shown by the continuously updated real-time quote of Xenon Pharmaceuticals stock.

Xenon Pharmaceuticals facts

  • Company: Xenon Pharmaceuticals Inc.
  • ISIN: CA98420N1050
  • Ticker: XENE
  • Primary exchange: Nasdaq
  • Market capitalization: USD 3.2 billion (as of October 16, 2026)
  • 52-week range: USD 33.38-72.66 (as of October 16, 2026)
  • Sector / Industry: Healthcare / Biotechnology

Market context: Market report S&P 500.

More news and analyses on Xenon Pharmaceuticals stock

Disclaimer...
en | CA98420N1050 | XENE | boerse | 70352969 | bgmi